Welcome to the December 2025 newsletter from the KRAS Patient Gateway—your place for the latest research and information about KRAS-positive lung cancer.
Non-small cell lung cancer (NSCLC) with a KRAS G12C mutation is treated with immunotherapy as the first treatment approach. If the cancer begins to grow again, two targeted therapy drugs, adagrasib and sotorasib, are available for treatment.
In data presented at the 2025 World Conference on Lung Cancer, researchers shared progress in bringing targeted therapy to patients as part of an initial treatment regimen.
Researchers looked at data from two studies -- the phase 1 LOXO-RAS-2001 study and the phase 3 SUNRAY-01 study – that tested the use of olomorasib, a highly specific KRAS G12C inhibitor, combined with chemoimmunotherapy as a first-line treatment for patients with advanced KRAS G12C-positive NSCLC. More than half of patients on this regimen (61%) had their tumors shrink or disappear, and 90% benefited (disease control rate) from this combination. This promising work continues in the phase 3 SUNRAY-01 clinical trial and offers hope for a new treatment option for newly diagnosed patients with KRAS G12C-positive lung cancer.
Looking beyond the KRAS G12C mutation, researchers are also busy developing treatments for other KRAS alterations (such as KRAS G12D).
There is also exciting work in understanding more about all KRAS-positive lung cancer—such as the identification and characterization of co-mutations STK-11 and TTF-1—to understand more details about cancer development and improve our ability to target the disease.
There is impactful research being conducted to help patients with KRAS-positive lung cancer have the best possible outcomes from their disease.
Research News
KRAS G12C-Mutated NSCLC: Current Treatment Paradigms
Lung Cancer News Today
June 18, 2025
Lung Cancer Monthly Rewind: Key News and Expert Insights You May Have Missed in September 2025
Lung Cancer News Today
October 7, 2025
Rafeh Naqash: The Role of STK11/KRAS in Early Stage NSCLC
OncoDaily
August 9, 2025
Lung Cancer Biomarker TTF-1 Guides KRAS-Targeted Therapy
Lung Cancer News Today
May 28, 2025
Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges
Nature Online
November 28, 2025
Get Connected
Join Us for the KRAS Virtual Meetup
This is an easy way to build your community. On the third Wednesday of each month, you can connect with others who understand what it’s like to live with KRAS-positive lung cancer. The next KRAS Meetup is happening on Jan 21, 2026, 12:00 pm ET. Register for free to get a confirmation email with details about how to join the virtual meeting. New attendees are always welcome and encouraged to join!
Can’t make it? Don’t worry, there’s a full list of virtual meetups to fit your schedule.
Mark Your Calendar
May 1-3, 2026
HOPE Summit in Dallas, TX
Save the date for HOPE Summit, a warm and uplifting in person gathering where lung cancer survivors, patients, and caregivers come together to learn, connect, and feel inspired. Attendees will hear from powerful speakers and experts on everyday issues that matter most, including mental and sexual health, financial guidance, and navigating care. You will also meet peers who understand the journey and can offer meaningful support. With free registration, travel grants, and helpful resources, this is the perfect time to plan your attendance. You can learn more about the event and complete the interest form for alerts when registration opens.
Have You Seen?
Veteran Voices: Surgery to Survivorship at the VA
Meet Michael O’Donnell, a Vietnam veteran whose remarkable five-year journey with stage IV KRAS-positive lung cancer is reshaping how veterans think about care and screening. Michael is using his experience as a lung cancer survivor who is treated through the VA health system to help others ask the right questions and get the support they need. Learn more.
Tips to Manage Scanxiety
Many people struggle with feelings of anxiety or worry before medical exams, such as an MRI or a CT scan. LUNGevity has compiled six tips to help patients and caregivers manage this “scanxiety.” Learn more.
Losing Significant Weight Loss During Treatment
Losing significant weight and muscle mass during lung cancer treatment is common. However, often these symptoms are not a side effect of treatment. They can be due to a condition called cachexia. Learn more about this condition—including who is at risk for it, how to recognize it, and what can be done to address the symptoms.
…and there is always so much more to explore on the KRAS Patient Gateway.
If you were forwarded this email and you’d like to subscribe to this newsletter, you can sign up here.
If you need further assistance along your lung cancer journey, please email us at support@lungevity.org. Our team is always here to assist you.
